Tag Archives: visiongate

Healthcare Leadership Awards 2015_38

Az Business honors winners of Healthcare Leadership Awards

Az Business magazine honored winners of the 2015 Healthcare Leadership Awards Thursday in front of a packed house at the Arizona Grand Resort.

“The Healthcare Leadership Awards honor the women, men and institutions whose passion and innovation are saving lives, extending lives, and improving the quality of our lives,” said Cheryl Green, publisher for AZ Big Media, which publishes Az Business magazine.

Sponsors included Blue Cross Blue Shield of Arizona, Arizona Central Credit Union and CodeRed-I.

Here are the winners of the 2015 Healthcare Leadership Awards:

Healthcare advocate/educator of the year: Catherine Ivy, Ben & Catherine Ivy Foundation

Behavioral health company of the year: Southwest Behavioral Health Services

Bioscience company of the year: VisionGate

Insurance provider of the year: Blue Cross Blue Shield of Arizona

Legal advocate of the year: Martin L. Shultz, Brownstein Hyatt Farber Schreck

Medical company of the year: SynCardia

Medical research company of the year: Barrow Neurological Institute

Researcher of the year: Dr. Daniel D. Von Hoff, TGen and HonorHealth

Physician of the year: Robert J. Arceci, M.D., Phoenix Children’s Hospital

Healthcare executive of the year: Tim Bricker, Chandler Regional and Mercy Gilbert medical centers

Medical center or hospital of the year: Cancer Treatment Centers of America at Western Regional Medical Center

Lifetime achievement award: Peter Fine, Banner Health

“The word visionary is thrown around often, but it’s not often that it really fits,” said Michael Gossie, editor in chief for Az Business magazine. “But that’s not the case with Peter Fine. He is a visionary. And it took a visionary to take two healthcare systems with very different histories and grow it into a healthcare company that generates more than $5 billion in annual revenue, operates 28 acute-care hospitals across seven states, and employs more than 45,000 employees in Arizona.”


Healthcare Leadership Awards 2015 Photos

Healthcare Leadership Awards 2015_12
Healthcare Leadership Awards 2015_12
Healthcare Leadership Awards 2015_14
Healthcare Leadership Awards 2015_14
Healthcare Leadership Awards 2015_13
Healthcare Leadership Awards 2015_13
Healthcare Leadership Awards 2015_06
Healthcare Leadership Awards 2015_06
Healthcare Leadership Awards 2015_07
Healthcare Leadership Awards 2015_07
Healthcare Leadership Awards 2015_08
Healthcare Leadership Awards 2015_08
Healthcare Leadership Awards 2015_15
Healthcare Leadership Awards 2015_15
Healthcare Leadership Awards 2015_16
Healthcare Leadership Awards 2015_16
Healthcare Leadership Awards 2015_02
Healthcare Leadership Awards 2015_02
Healthcare Leadership Awards 2015_09
Healthcare Leadership Awards 2015_09
Healthcare Leadership Awards 2015_10
Healthcare Leadership Awards 2015_10
Healthcare Leadership Awards 2015_11
Healthcare Leadership Awards 2015_11
Healthcare Leadership Awards 2015_04
Healthcare Leadership Awards 2015_04
Healthcare Leadership Awards 2015_05
Healthcare Leadership Awards 2015_05
Healthcare Leadership Awards 2015_01
Healthcare Leadership Awards 2015_01
Healthcare Leadership Awards 2015_17
Healthcare Leadership Awards 2015_17
Healthcare Leadership Awards 2015_18
Healthcare Leadership Awards 2015_18
Healthcare Leadership Awards 2015_19
Healthcare Leadership Awards 2015_19
Healthcare Leadership Awards 2015_20
Healthcare Leadership Awards 2015_20
Healthcare Leadership Awards 2015_21
Healthcare Leadership Awards 2015_21
Healthcare Leadership Awards 2015_22
Healthcare Leadership Awards 2015_22
Healthcare Leadership Awards 2015_23
Healthcare Leadership Awards 2015_23
Healthcare Leadership Awards 2015_24
Healthcare Leadership Awards 2015_24
Healthcare Leadership Awards 2015_25
Healthcare Leadership Awards 2015_25
Healthcare Leadership Awards 2015_26
Healthcare Leadership Awards 2015_26
Healthcare Leadership Awards 2015_27
Healthcare Leadership Awards 2015_27
Healthcare Leadership Awards 2015_28
Healthcare Leadership Awards 2015_28
Healthcare Leadership Awards 2015_29
Healthcare Leadership Awards 2015_29
Healthcare Leadership Awards 2015_30
Healthcare Leadership Awards 2015_30
Healthcare Leadership Awards 2015_31
Healthcare Leadership Awards 2015_31
Healthcare Leadership Awards 2015_32
Healthcare Leadership Awards 2015_32
Healthcare Leadership Awards 2015_33
Healthcare Leadership Awards 2015_33
Healthcare Leadership Awards 2015_34
Healthcare Leadership Awards 2015_34
Healthcare Leadership Awards 2015_35
Healthcare Leadership Awards 2015_35
Healthcare Leadership Awards 2015_36
Healthcare Leadership Awards 2015_36
Healthcare Leadership Awards 2015_37
Healthcare Leadership Awards 2015_37
Healthcare Leadership Awards 2015_38
Healthcare Leadership Awards 2015_38
Healthcare Leadership Awards 2015_39
Healthcare Leadership Awards 2015_39
Healthcare Leadership Awards 2015_40
Healthcare Leadership Awards 2015_40
Healthcare Leadership Awards 2015_41
Healthcare Leadership Awards 2015_41
Healthcare Leadership Awards 2015_42
Healthcare Leadership Awards 2015_42

cancer

Renowned surgeon joins VisionGate advisory board

VisionGate, Inc. a company that has developed a non-invasive test for the early detection of lung cancer, LuCED, announced that nationally renowned thoracic surgeon Dr. Harvey Pass has joined its Medical Advisory Board. Dr. Pass specializes in detecting, diagnosing and treating pleural mesothelioma and lung cancer. He is also a renowned cancer researcher widely known for identifying a mesothelioma biomarker called osteopontin, which helped develop a blood test to detect mesothelioma.

Dr. Pass serves as vice chairman of Research for the Department of Cardiothoracic Surgery at NYU Langone Medical Center, professor of Thoracic Oncology and chief of Thoracic Surgery.

“I am delighted to collaborate with VisionGate and to provide objective advice and opinion on ways to advance the diagnosis and treatment of lung cancer,” Dr. Pass said. “Recent technologic advances hold tremendous potential and I’m happy to be involved in the company’s journey.”

Dr. Pass dedicates a significant amount of time to patient advocacy groups and research that provides new alternatives for patients. He was one of the first thoracic surgeons to use intraoperative photodynamic therapy (PDT) and laser-activated injections. He was chairman of the Lung Cancer Alliance’s Medical Advisory Board for five years, chairman of the American Society of Clinical Oncology (ASCO) Education Committee on Lung Cancer for two years, former board director for the Alliance for Lung Cancer, and is current chairman of the Publications Committee for the International Association for the Study of Lung Cancer (IASLC) and board director for the Addario Lung Cancer Medical Institute. He also co-founded the Mesothelioma Applied Research Foundation, dedicated to funding research for a cure and providing support to mesothelioma patients.

Dr. Harvey Pass is a Phi Beta Kappa graduate of the Johns Hopkins University and Duke Medical School. He joins nine other members of VisionGate’s Medical Advisory Board including:

• Terence J. Colgan, MD – head of the Gynecological and Cytopathology sections of Mount Sinai Hospital and a professor in the Laboratory Medicine & Pathobiology and Obstetrics & Gynecology departments at the University of Toronto

• Robb W. Glenny, MD – division head of Pulmonary and Critical Care Medicine and professor of Medicine, Physiology and Biophysics at the University of Washington

• Edward P. Ingenito, MD, PhD – assistant professor of Medicine at Harvard Medical School

• Gene F. Pawlick, MD – former medical director at Kaiser Permanente Medical Group, Regional References Laboratories in Berkeley and Richmond, CA

• James Mulshine, MD – associate provost for Research and vice president director of Rush Hospital Translational Sciences Consortium

• Javier J. Zulueta, MD, FCCP – director of Pulmonary Services and associate professor of Medicine at the University of Navarra in Spain

• David Wilbur, MD, FACP – anatomic pathologist at Massachusetts General Hospital and professor of Pathology at Harvard Medical School

• Ralph Aye, MD – esophageal and thoracic surgeon at Swedish Medical Center in Seattle

• Harubumi Kato, MD, PhD – emeritus professor at Tokyo Medical College, honorary president of Niizashiki Central General Hospital and a professor at the International University of Health and Wealthfare

“We are honored that NYU’s Dr. Harvey Pass has joined VisionGate’s Medical Advisory Board,” Founder & CEO Alan Nelson, PhD said. “With his outstanding leadership and innovation in the management of lung disease, Dr. Pass is among the most recognized physicians in this arena. His perspective will complement the breadth of expertise that already exists on our board of world renowned physicians.”

For more background on VisionGate’s Medical Advisory Board or Board of Directors, visit www.visiongate3d.com.

healthcare

Az Business names Healthcare Leadership Awards finalists

Each year, AZ Business magazine hosts the Healthcare Leadership Awards to honor the women, men and institutions that bring excellence and innovation to Arizona’s healthcare sector.

Az Business is proud to announce the 2015 Healthcare Leadership Awards finalists, who were chosen by a panel of industry experts and will be recognized at the Healthcare Leadership Awards dinner and awards ceremony on April 9  at the Arizona Grand Resort. The finalists, in alphabetical order, are:

Abrazo Health — Arrowhead Hospital

Abrazo Health — Michele Finney

Affiliated Urologists — Dr. Mark Hong

Banner Health, Cardon Children’s Medical Center — Rachel Calendo

Banner Health — Peter Fine

Ben & Catherine Ivy Foundation — Catherine Ivy

Blue Cross Blue Shield of Arizona

Brownstein Hyatt Farber Schreck — Martin L. Shultz

Cancer Treatment Centers of America at Western Regional Medical Center

CTCA — Dr. Glen Weiss

Dedicated Health Solutions

Dignity Health — Barrow Neurological Institute

Dignity Health, Chandler Regional and Mercy Gilbert medical centers — Tim Bricker

Dignity Health — St. Joseph’s Hospital and Medical Center

HonorHealth and TGen — Dr. Daniel D. Von Hoff

HonorHealth – Virginia G. Piper Cancer Center

IASIS Healthcare — Tony Marinello

Insys Therapeutics

Magellan Health

Maricopa Integrated Health System — Dr. David Wisinger

Medtronic

Midwestern University — Kathleen Goeppinger

Quarles & Brady — Roger Morris

Phoenix Children’s Hospital – Dr. Robert J. Arceci

Radiant Research

Remuda Ranch

Snell and Wilmer – Richard Mallery

Sonora Quest Laboratories

Southwest Behavioral Health Services

SynCardia Systems

The CORE Institute — Dr. David Jacofsky

UnitedHealthcare of Arizona

University of Arizona Cancer Center

VisionGate

cancer

Dignity Health in Arizona invests in VisionGate

VisionGate has received financial backing from Dignity Health in Arizona for development of a revolutionary, non-invasive test for the early detection of lung cancer, the world’s deadliest cancer. Patient sputum samples are processed on the company’s patented Cell-CT® system – aptly named because it takes an optical CT scan of individual cells to generate digital, high-resolution, 3D images of each cell for early disease diagnosis, rare cell detection and research.

The investment aligns with Dignity Health’s commitment to provide patients with one of the most advanced lung disease programs in the Southwest through its Norton Thoracic Institute at Dignity Health St. Joseph’s Hospital and Medical Center.

“We are committed to bringing the most innovative advancements in health care to our patients,” President and CEO of Dignity Health, Arizona Service Area Linda Hunt said. “VisionGate has a very promising technology.”

VisionGate’s wholly owned clinical laboratory in Phoenix will provide analytical services using the Company’s LuCED® lung cancer test based on sputum (phlegm) samples from patients who collect three morning coughs at home. Published clinical data demonstrates a high degree of accuracy in detecting early stage lung cancer with few to no false positives. LuCED will be added to the Thoracic Institute’s lung cancer screening program as part of a formal clinical trial.

Dignity Health’s investment will support VisionGate’s goal to commercialize LuCED and make it available to the public in 2015 through the launch of the VisionGate Biosignatures Laboratory (VBL) headed by VisionGate’s President, Scarlett Spring.

“It is critically important to have the potential of our technology confirmed by an esteemed organization like Dignity Health,” VisionGate CEO Alan Nelson, PhD, said. “With support from Dignity Health, the Phoenix area will emerge as the epicenter for improving the lives of patients at risk of lung cancer.”

cancer

VisionGate earns two Best in Biz Awards for innovation

VisionGate, Inc. has been named a gold winner in two categories in the Best in Biz Awards 2014, the only independent business awards program judged by members of the press and industry analysts. VisionGate was awarded gold in the Most Innovative Company of the Year (Small) category and in the Most Innovative Product of the Year (SMB) category.

Awarded for its innovative technology, VisionGate’s revolutionary Cell-CT® can take a bodily sample – sputum, urine, blood, etc. – and essentially take a CT scan of each individual cell, which automatically determines normals from abnormals. Currently, cells are seen in 2D on a glass slide. This technology is transformational in that it allows physicians and scientists to see an individual cell in 3D on a computer for the very first time, allowing for more accurate and earlier detection of disease.

VisionGate was awarded Most Innovative Product for its LuCED® test, a non-invasive, take-home test that aids physicians in the early detection of lung cancer, the world’s deadliest cancer. Whether as a first-line screening or used in conjunction with the CT scan to eliminate the false positives, it provides significant hope to those at risk for lung cancer and for the 20 percent who are not considered high-risk, but are diagnosed with lung cancer each year. VisionGate’s LuCED test will be available to the public in early 2015.

This is the first time VisionGate has won a Best in Biz award. Its fourth annual North American program, this year was its most competitive yet. As in previous years, the program featured a large and distinguished judging panel comprised of members of the media who reviewed and scored the hundreds of award nominations. More than 550 award nominations were received this year in a variety of company, executive, team and product-focused categories. Nominations were fielded from public and private companies of all sizes, from virtually every major industry and region in the U.S. and Canada.

“We are honored to be recognized in two categories by the Best in Biz Awards,” said VisionGate Founder & CEO Dr. Alan Nelson. “This award is a result of our commitment to innovation as well as our unique team of engineers and scientists who continue to develop technologies that have tremendous potential to save lives.”

For a full list of gold, silver and bronze winners in Best in Biz Awards 2014, visit http://www.bestinbizawards.com/2014-winners/.

angel

Bioscience innovators will pitch at White Hat Investors

Bioindustry Associations from across the Rocky Mountain Southwest Region are coming together to present an opportunity for Angels, Venture Capitalists and Strategic Investors to connect with the biotech and healthcare investment opportunities from across the Rocky Mountain Southwest states at White Hat Investors 2014 in Phoenix, Arizona on September 17 and 18, 2014.

“The West was won by innovators, investors, and prospectors who understood the value of discovery and accepted the challenge of investing in new frontiers,” shared Joan Koerber-Walker, president and CEO of the Arizona Bioindustry Association (AZBio). “Now, industry leaders and accredited investors have the opportunity to meet a new generation of biotech and healthcare pioneers at White Hat 2014, the first annual biotech and healthcare investor conference that showcases the best of the Rocky Mountain Southwest Region.”

White Hat Presenting Companies were selected from the region’s emerging innovation leaders in the fields of Diagnostics, Therapeutics, Medical Devices, and Health IT. Presenting companies are developing lifesaving and life improving innovations that will benefit people today and for generations to come while addressing some of our greatest health challenges including cancer, cardiovascular and pulmonary disease, neurological disorders, infectious disease, and more.

On September 17th, over 400 life science industry leaders will gather to view a company showcase, browse a student discovery zone and listen to presentations from local life science entrepreneurs on the BioAccel Best of the Best Stage from 3:00 p.m. – 6:00 p.m. in the North Ballroom of the Phoenix Convention Center. Free and open to the general public, it presents an opportunity for members of the community to connect with the region’s fastest growing innovation sector. The public pre-event will be followed at 6:00 p.m. by the AZBio Awards gala (registration required) honoring life science pioneer Roy Curtiss, III, PhD; Charles Arntzen, PhD, the Arizona State University Researcher who, with his team, played a key role in the development of ZMAPP, the experimental Ebola drug given to two health workers who were sickened by the deadly virus earlier this year; W.J. “Jim” Lane, Mayor of the City of Scottsdale for his work in developing the Scottsdale Cure Corridor; innovative educator Miles Orchinik, PhD of the School of Life Sciences at Arizona State University; Jack B. Jewett of the Flinn Foundation for leadership of the longest running statewide bioscience development initiative in the United States; emerging technology leaders SenesTech, Pinnacle Transplant Technologies, and Cancer Prevention Pharmaceuticals along with the 2014 Arizona Bioscience Company of the Year, Insys Therapeutics, Inc.

White Hat events continue on September 18th at the Hyatt Regency in downtown Phoenix with presentations by privately-held life science companies presenting to attending representatives of family offices, investment funds, corporate investment/business development professionals for life science oriented firms (strategic investors), granting foundations, venture capital firms, and accredited investors. In addition to great company presentations in the areas of Medical Devices, Diagnostics, Therapeutics and Health IT, White Hat includes THREE general sessions featuring panel discussions on the investment environment from the perspective of Angels, Strategic Investors, and VCs.
Presenting Companies were selected from the Rocky Mountain Southwest’s emerging innovator leaders in the fields of: Diagnostics, Therapeutics, Medical Devices and Health IT and include:

• Aviratek, LLC
• Breezing
• Calimmune, Inc.
• CardioCreate, Inc.
• Convoy Therapeutics
• DiscGenics
• Elutin Vascular Inc.
• EndoShape, Inc
• Fluonic
• Imagenonics LLC
• Iron Horse Diagnostics
• INanoBio
• Kalos Therapeutics
• Kulira Technologies
• Meditope Biosciences, Inc.
• MSDx
• NeuroRecovery Technologies, Inc.
• NuvoMed
• NuvOx Pharma
• Pediatric Bioscience, Inc
• Portable Genomics, Inc.
• MedTalk Companion (Real Phone Corp)
• Recursion Pharmaceuticals
• RiboMed Biotechnologies
• Savoy Pharmaceuticals
• SenesTech
• Skylit Medical
• Sonoran Biosciences
• T-MedRobotics
• Valley Fever Solutions
• ValveXchange
• ViroCyt
• VisionGate
• Yolia Health

scarlett_spring

Scarlett Spring – Most Influential Women in Arizona Business

Scarlett SpringPresident, VisionGate
Spring is charged with bringing an early cancer detection technology utilizing 3D imaging to market. Her background includes 19 years at AstraZeneca and COO at GPEC.

Greatest accomplishment: “Ability to shift from launching billion-dollar brands to taking a start-up from angel investment to commercialization.”

Surprising fact: “Every day during my drive to work, I talk to my mom on the phone.”

Most Influential Women in Arizona Business – Every year in its July/August issue, Az Business Magazine celebrates the amazing women who make an impact on Arizona business.

Click here to see all of the 2014 Most Influential Women.

AZ Big Media honors Most Influential Women

azbigmedia_mostinfluentialwomen_srp2014-001
azbigmedia_mostinfluentialwomen_srp2014-001
azbigmedia_mostinfluentialwomen_srp2014-081
azbigmedia_mostinfluentialwomen_srp2014-081
azbigmedia_mostinfluentialwomen_srp2014-082
azbigmedia_mostinfluentialwomen_srp2014-082
azbigmedia_mostinfluentialwomen_srp2014-083
azbigmedia_mostinfluentialwomen_srp2014-083
azbigmedia_mostinfluentialwomen_srp2014-084
azbigmedia_mostinfluentialwomen_srp2014-084
azbigmedia_mostinfluentialwomen_srp2014-086
azbigmedia_mostinfluentialwomen_srp2014-086
azbigmedia_mostinfluentialwomen_srp2014-002
azbigmedia_mostinfluentialwomen_srp2014-002
azbigmedia_mostinfluentialwomen_srp2014-003
azbigmedia_mostinfluentialwomen_srp2014-003
azbigmedia_mostinfluentialwomen_srp2014-004
azbigmedia_mostinfluentialwomen_srp2014-004
azbigmedia_mostinfluentialwomen_srp2014-005
azbigmedia_mostinfluentialwomen_srp2014-005
azbigmedia_mostinfluentialwomen_srp2014-006
azbigmedia_mostinfluentialwomen_srp2014-006
azbigmedia_mostinfluentialwomen_srp2014-007
azbigmedia_mostinfluentialwomen_srp2014-007
azbigmedia_mostinfluentialwomen_srp2014-008
azbigmedia_mostinfluentialwomen_srp2014-008
azbigmedia_mostinfluentialwomen_srp2014-009
azbigmedia_mostinfluentialwomen_srp2014-009
azbigmedia_mostinfluentialwomen_srp2014-010
azbigmedia_mostinfluentialwomen_srp2014-010
azbigmedia_mostinfluentialwomen_srp2014-011
azbigmedia_mostinfluentialwomen_srp2014-011
azbigmedia_mostinfluentialwomen_srp2014-012
azbigmedia_mostinfluentialwomen_srp2014-012
azbigmedia_mostinfluentialwomen_srp2014-013
azbigmedia_mostinfluentialwomen_srp2014-013
azbigmedia_mostinfluentialwomen_srp2014-014
azbigmedia_mostinfluentialwomen_srp2014-014
azbigmedia_mostinfluentialwomen_srp2014-015
azbigmedia_mostinfluentialwomen_srp2014-015
azbigmedia_mostinfluentialwomen_srp2014-016
azbigmedia_mostinfluentialwomen_srp2014-016
azbigmedia_mostinfluentialwomen_srp2014-017
azbigmedia_mostinfluentialwomen_srp2014-017
azbigmedia_mostinfluentialwomen_srp2014-018
azbigmedia_mostinfluentialwomen_srp2014-018
azbigmedia_mostinfluentialwomen_srp2014-020
azbigmedia_mostinfluentialwomen_srp2014-020
azbigmedia_mostinfluentialwomen_srp2014-019
azbigmedia_mostinfluentialwomen_srp2014-019
azbigmedia_mostinfluentialwomen_srp2014-021
azbigmedia_mostinfluentialwomen_srp2014-021
azbigmedia_mostinfluentialwomen_srp2014-079
azbigmedia_mostinfluentialwomen_srp2014-079
azbigmedia_mostinfluentialwomen_srp2014-022
azbigmedia_mostinfluentialwomen_srp2014-022
azbigmedia_mostinfluentialwomen_srp2014-023
azbigmedia_mostinfluentialwomen_srp2014-023
azbigmedia_mostinfluentialwomen_srp2014-024
azbigmedia_mostinfluentialwomen_srp2014-024
azbigmedia_mostinfluentialwomen_srp2014-025
azbigmedia_mostinfluentialwomen_srp2014-025
azbigmedia_mostinfluentialwomen_srp2014-026
azbigmedia_mostinfluentialwomen_srp2014-026
azbigmedia_mostinfluentialwomen_srp2014-027
azbigmedia_mostinfluentialwomen_srp2014-027
azbigmedia_mostinfluentialwomen_srp2014-028
azbigmedia_mostinfluentialwomen_srp2014-028
azbigmedia_mostinfluentialwomen_srp2014-029
azbigmedia_mostinfluentialwomen_srp2014-029
azbigmedia_mostinfluentialwomen_srp2014-030
azbigmedia_mostinfluentialwomen_srp2014-030
azbigmedia_mostinfluentialwomen_srp2014-031
azbigmedia_mostinfluentialwomen_srp2014-031
azbigmedia_mostinfluentialwomen_srp2014-032
azbigmedia_mostinfluentialwomen_srp2014-032
azbigmedia_mostinfluentialwomen_srp2014-033
azbigmedia_mostinfluentialwomen_srp2014-033
azbigmedia_mostinfluentialwomen_srp2014-034
azbigmedia_mostinfluentialwomen_srp2014-034
azbigmedia_mostinfluentialwomen_srp2014-035
azbigmedia_mostinfluentialwomen_srp2014-035
azbigmedia_mostinfluentialwomen_srp2014-036
azbigmedia_mostinfluentialwomen_srp2014-036
azbigmedia_mostinfluentialwomen_srp2014-037
azbigmedia_mostinfluentialwomen_srp2014-037
azbigmedia_mostinfluentialwomen_srp2014-038
azbigmedia_mostinfluentialwomen_srp2014-038
azbigmedia_mostinfluentialwomen_srp2014-039
azbigmedia_mostinfluentialwomen_srp2014-039
azbigmedia_mostinfluentialwomen_srp2014-040
azbigmedia_mostinfluentialwomen_srp2014-040
azbigmedia_mostinfluentialwomen_srp2014-041
azbigmedia_mostinfluentialwomen_srp2014-041
azbigmedia_mostinfluentialwomen_srp2014-042
azbigmedia_mostinfluentialwomen_srp2014-042
azbigmedia_mostinfluentialwomen_srp2014-044
azbigmedia_mostinfluentialwomen_srp2014-044
azbigmedia_mostinfluentialwomen_srp2014-045
azbigmedia_mostinfluentialwomen_srp2014-045
azbigmedia_mostinfluentialwomen_srp2014-046
azbigmedia_mostinfluentialwomen_srp2014-046
azbigmedia_mostinfluentialwomen_srp2014-047
azbigmedia_mostinfluentialwomen_srp2014-047
azbigmedia_mostinfluentialwomen_srp2014-048
azbigmedia_mostinfluentialwomen_srp2014-048
azbigmedia_mostinfluentialwomen_srp2014-049
azbigmedia_mostinfluentialwomen_srp2014-049
azbigmedia_mostinfluentialwomen_srp2014-050
azbigmedia_mostinfluentialwomen_srp2014-050
azbigmedia_mostinfluentialwomen_srp2014-052
azbigmedia_mostinfluentialwomen_srp2014-052
azbigmedia_mostinfluentialwomen_srp2014-053
azbigmedia_mostinfluentialwomen_srp2014-053
azbigmedia_mostinfluentialwomen_srp2014-054
azbigmedia_mostinfluentialwomen_srp2014-054
azbigmedia_mostinfluentialwomen_srp2014-056
azbigmedia_mostinfluentialwomen_srp2014-056
azbigmedia_mostinfluentialwomen_srp2014-060
azbigmedia_mostinfluentialwomen_srp2014-060
azbigmedia_mostinfluentialwomen_srp2014-062
azbigmedia_mostinfluentialwomen_srp2014-062
azbigmedia_mostinfluentialwomen_srp2014-063
azbigmedia_mostinfluentialwomen_srp2014-063
azbigmedia_mostinfluentialwomen_srp2014-064
azbigmedia_mostinfluentialwomen_srp2014-064
azbigmedia_mostinfluentialwomen_srp2014-065
azbigmedia_mostinfluentialwomen_srp2014-065
azbigmedia_mostinfluentialwomen_srp2014-066
azbigmedia_mostinfluentialwomen_srp2014-066
azbigmedia_mostinfluentialwomen_srp2014-068
azbigmedia_mostinfluentialwomen_srp2014-068
azbigmedia_mostinfluentialwomen_srp2014-069
azbigmedia_mostinfluentialwomen_srp2014-069
azbigmedia_mostinfluentialwomen_srp2014-071
azbigmedia_mostinfluentialwomen_srp2014-071
azbigmedia_mostinfluentialwomen_srp2014-072
azbigmedia_mostinfluentialwomen_srp2014-072
azbigmedia_mostinfluentialwomen_srp2014-073
azbigmedia_mostinfluentialwomen_srp2014-073
azbigmedia_mostinfluentialwomen_srp2014-074
azbigmedia_mostinfluentialwomen_srp2014-074
azbigmedia_mostinfluentialwomen_srp2014-080
azbigmedia_mostinfluentialwomen_srp2014-080
azbigmedia_mostinfluentialwomen_srp2014-075
azbigmedia_mostinfluentialwomen_srp2014-075
azbigmedia_mostinfluentialwomen_srp2014-076
azbigmedia_mostinfluentialwomen_srp2014-076
azbigmedia_mostinfluentialwomen_srp2014-082
azbigmedia_mostinfluentialwomen_srp2014-082
azbigmedia_mostinfluentialwomen_srp2014-077
azbigmedia_mostinfluentialwomen_srp2014-077
azbigmedia_mostinfluentialwomen_srp2014-079
azbigmedia_mostinfluentialwomen_srp2014-079
azbigmedia_mostinfluentialwomen_srp2014-084
azbigmedia_mostinfluentialwomen_srp2014-084
azbigmedia_mostinfluentialwomen_srp2014-078
azbigmedia_mostinfluentialwomen_srp2014-078
azbigmedia_mostinfluentialwomen_srp2014-083
azbigmedia_mostinfluentialwomen_srp2014-083
azbigmedia_mostinfluentialwomen_srp2014-004
azbigmedia_mostinfluentialwomen_srp2014-004
azbigmedia_mostinfluentialwomen_srp2014-006
azbigmedia_mostinfluentialwomen_srp2014-006
azbigmedia_mostinfluentialwomen_srp2014-007
azbigmedia_mostinfluentialwomen_srp2014-007
azbigmedia_mostinfluentialwomen_srp2014-008
azbigmedia_mostinfluentialwomen_srp2014-008
azbigmedia_mostinfluentialwomen_srp2014-009
azbigmedia_mostinfluentialwomen_srp2014-009
azbigmedia_mostinfluentialwomen_srp2014-011
azbigmedia_mostinfluentialwomen_srp2014-011
azbigmedia_mostinfluentialwomen_srp2014-012
azbigmedia_mostinfluentialwomen_srp2014-012
azbigmedia_mostinfluentialwomen_srp2014-013
azbigmedia_mostinfluentialwomen_srp2014-013
azbigmedia_mostinfluentialwomen_srp2014-015
azbigmedia_mostinfluentialwomen_srp2014-015
azbigmedia_mostinfluentialwomen_srp2014-016
azbigmedia_mostinfluentialwomen_srp2014-016
azbigmedia_mostinfluentialwomen_srp2014-017
azbigmedia_mostinfluentialwomen_srp2014-017
azbigmedia_mostinfluentialwomen_srp2014-037
azbigmedia_mostinfluentialwomen_srp2014-037
azbigmedia_mostinfluentialwomen_srp2014-038
azbigmedia_mostinfluentialwomen_srp2014-038
azbigmedia_mostinfluentialwomen_srp2014-054
azbigmedia_mostinfluentialwomen_srp2014-054
azbigmedia_mostinfluentialwomen_srp2014-056
azbigmedia_mostinfluentialwomen_srp2014-056
azbigmedia_mostinfluentialwomen_srp2014-060
azbigmedia_mostinfluentialwomen_srp2014-060
azbigmedia_mostinfluentialwomen_srp2014-063
azbigmedia_mostinfluentialwomen_srp2014-063
azbigmedia_mostinfluentialwomen_srp2014-078
azbigmedia_mostinfluentialwomen_srp2014-078



They are the best business minds in Arizona. They are innovators, trailblazers and leaders of men.

They are Az Business magazine’s Most Influential Women in Arizona Business for 2014, as selected by the editorial team at Az Business magazine and a panel of industry experts. The Most Influential Women were honored Thursday at a reception at The Venue in Scottsdale.

“While their resumes and career paths may differ, the women we selected have all procured influence in their respective fields through hard-earned track records of profitability, business ethics and leadership,” said AZ Big Media Publisher Cheryl Green. “Az Business magazine is proud to congratulate the women who earned the right to call themselves one of the Most Influential Women in Arizona Business. They are changing the face of Arizona business.”

The women selected to this prestigious list for 2014 are:

Nazneen Aziz, Ph.D, senior vice president and chief research officer, Phoenix Children’s Hospital
Trish Bear, president and CEO, I-ology
Dr. Amy Beiter, president and CEO, Carondelet St. Mary’s Hospital and Carondelet Heart & Vascular Institute
Janet G. Betts, member, Sherman & Howard
Kristin Bloomquist, executive vice president and general manager, Cramer-Krasselt
Delia Carlyle, councilwoman, Ak-Chin Indian Community
Luci Chen, partner, Arizona Center for Cancer Care
Mary Collum, senior vice president, National Bank of Arizona
Kathy Coover, co-founder, Isagenix International
Janna Day, managing partner, Brownstein Hyatt Farber Schreck
Karen Dickinson, shareholder, Polsinelli
Michele Finney, CEO, Abrazo Health
Susan Frank, CEO, Desert Schools Federal Credit Union
Leah Freed, managing shareholder, Ogletree Deakins
Deborah Griffin, president of the board of directors, Gila River Casinos
Mary Ann Guerra, CEO, BioAccel
Deb Gullett, senior specialist, Gallagher & Kennedy
Diane Haller, partner, Quarles & Brady
Maria Harper-Marinick, executive vice chancellor and provost, Maricopa Community Colleges
Catherine Hayes, principal, hayes architecture/interiors inc.
Camille Hill, president, Merestone
Chevy Humphrey, president and CEO, Arizona Science Center
Heidi Jannenga, founder, WebPT
Kara Kalkbrenner, acting fire chief, City of Phoenix
Lynne King Smith, CEO, TicketForce
Joan Koerber Walker, CEO, Arizona Bioindustry Association
Karen Kravitz, president and head of conceptology, Commotion Promotions
Deb Krmpotic, CEO, Banner Estrella Medical Center
Jessica Langbaum, PhD, principal scientist, Banner Alzheimer’s Institute
Georgia Lord, mayor, City of Goodyear
Sherry Lund, founder, Celebration Stem Cell Centre
Teresa Mandelin, CEO, Southwestern Business Financing Corporation
Shirley Mays, dean, Arizona Summit Law School
Ann Meyers-Drysdale, vice president, Phoenix Mercury and Phoenix Suns
Marcia L. Mintz, president, John C. Lincoln Health Foundation
Martha C. Patrick, shareholder, Burch & Cracchiolo, P.A.
Stephanie J. Quincy, partner, Steptoe & Johnson
Barb Rechterman, chief marketing officer, GoDaddy
Marian Rhodes, senior vice president, Arizona Diamondbacks
Joyce Santis, chief operating officer, Sonora Quest Laboratories
Gena Sluga, partner, Christian Dichter & Sluga
Beth Soberg, CEO, UnitedHealthcare of Arizona
Scarlett Spring, president, VisionGate
Patrice Strong-Register, managing partner, JatroBiofuels
Sarah A. Strunk, director, Fennemore Craig, P.C.
Marie Sullivan, president and CEO, Arizona Women’s Education & Employment
Nancy K. Sweitzer, MD, director, UA’s Sarver Heart Center
Dana Vela, president, Sunrise Schools and Tots Unlimited
Alicia Wadas, COO, The Lavidge Company
Ginger Ward, CEO, Southwest Human Development

In addition to the Most Influential Women in Arizona Business, Az Business also selects five “Generation Next” women who are making an impact on Arizona, even though they are less than 40 years old. Those women selected for 2014 are:

Anca Bec, 36, business development officer, Alliance Bank of Arizona
Alison R. Christian, 32, shareholder, Christian Dichter & Sluga, P.C.
Jaime Daddona, 38, senior associate, Squire Patton Boggs
Nancy Kim, 36, owner, Spectrum Dermatology
Jami Reagan, 35, owner, Shine Factory Public Relations

To select the best and brightest women to recognize each year, the editor and publisher of Az Business magazine compile a list of almost 1,000 women from every facet of Arizona’s business landscape — banking, law, healthcare, bioscience, real estate, technology, manufacturing, retail, tourism, energy, accounting and nonprofits. Once that list is compiled, we vet the list, narrow it down to about 150 women who we feel are most deserving, and then submit the list to 20 of their peers — female leaders from a variety or industries — and ask them to vote. If they want to vote for someone whose name is not on the list of those submitted for consideration, voters are invited to write in the names of women who they think deserve to members of this exclusive club.

Az Business also does not allow a woman to appear on the list most than once.

cancer

VisionGate Adds 3 Prominent Directors

VisionGate Inc., an in vitro diagnostics company that has developed the patented Cell-CT®, a 3D cell imaging platform being utilized in early disease detection, recently added three new esteemed business leaders to its Board of Directors. The directors come on board at a pivotal time for VisionGate, as its revolutionary, non-invasive test for the early detection of lung cancer – LuCED® – is poised to enter the market.

Robert A. Heft, PhD is chief executive officer of ILIT BioVentures, an early stage company developing gene therapy for rare metabolic disorders. Dr. Heft is former president and CEO of Enobia Pharmaceuticals, Inc. In 2012, he sold Enobia to Alexion Pharmaceuticals Inc. for $1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Prior to Enobia, Dr. Heft held several senior positions with BioMarin Pharmaceutical Inc., Continental Pharma Cryosan, Inc. and IBEX Technologies, which he founded. Dr. Heft received a bachelor’s degree in mechanical engineering from McGill University and a master’s degree in nuclear engineering from Cornell University before obtaining his PhD from the Massachusetts Institute of Technology in genetic engineering/radiological sciences. Dr. Heft currently is a member of the Board of Directors of several companies developing therapeutics for Orphan disorders.

Thomas J. Miller is the founder of GreyBird Ventures, an umbrella company for consulting, investment and management opportunities. Prior to founding GreyBird Ventures, Mr. Miller served in numerous executive roles, most recently as CEO of the Customer Solutions Division at Siemens Healthcare where he was responsible for all downstream activities regarding healthcare, IT and new services, managing 26,000 employees in more 130 countries. Mr. Miller has been featured in Diagnostic Imaging magazine in its cover story on “The 20 Most Influential People in Diagnostic Radiology”. After receiving a degree in nuclear engineering from the University of Massachusetts at Lowell, Miller earned a master’s degree in medical physics from the Harvard/MIT Health Sciences and Technology joint program. During his academic career, he worked at Los Alamos, the Swiss Institute for Nuclear Research (now the Paul Scherer Institute), Brookhaven National Laboratory, and Massachusetts General Hospital as a research associate in radiation biophysics.

Gene Pawlick, MD, was recently the medical director at Kaiser Permanente Medical Group, Regional Reference Laboratories in Berkeley and Richmond, California. These laboratories comprise the largest reference clinical laboratory organization in the Kaiser Permanente system, performing more than 70 percent of all laboratory testing at Kaiser Permanente-Northern California. While there, he pioneered clinical studies in the area of cancer screening and diagnosis and has participated in related hearings at the FDA as a field expert. Dr. Pawlick earned his medical degree from Saint Louis University School of Medicine and completed his residency in anatomic and clinical pathology at Kaiser Permanente Medical Center in San Francisco.

Dr. Heft, Mr. Miller and Dr. Pawlick join three existing VisionGate board members. Together, they will provide timely strategic counsel to VisionGate’s management and help guide the overall direction of the company.

VisionGate, 3D Cellular Imaging - AZ Business Magazine September/October 2011

VisionGate Uses 3D Imaging To Detect Lung Cancer

In September 2010, the City of Phoenix, in partnership with VisionGate, opened the world’s first biomedical 3D cellular imaging lab.

The Cell-CT research lab is located on the Phoenix Biomedical Campus in downtown Phoenix.

A year later, VisionGate is well on its way to developing a revolutionary non-invasive test for the early detection of lung cancer. This summer, company representatives presented groundbreaking data at the International Association for the Study of Lung Cancer’s 14th World Conference on Lung Cancer in Amsterdam, Netherlands.VisionGate 3D Imaging

The data showed how adjunctive use of its LuCED™ test can improve the utility of low dose X-ray computed tomography (CT) screening for the early detection of lung cancer in high-risk individuals. LuCED uses VisionGate’s revolutionary automated 3D cell imaging platform, the Cell-CT™, which generates high-resolution 3D biosignatures from intact cells using a sputum sample.

Dr. Claudia Henschke, a lung cancer researcher at the Biodesign Institute at Arizona State University who is also a practicing physician at Mount Sinai Medical Center in New York City, serves as a leader of the International Early Lung Cancer Action Program. She is co-author of a pioneering study of the benefits of CT scans for lung cancer.

“Today, almost all patients diagnosed with lung cancer in the U.S. die. The NLST study results released last November confirmed our initial findings showing that CT scans can find lung cancers in their earliest stage, when up to 92 percent can be cured,” Henschke said.

The proposed first use of LuCED as an adjunct to CT screening reflects the results of the National Cancer Institute’s (NCI) landmark National Lung Screening Trial (NLST) of more than 53,000 current and former heavy smokers, which showed that low-dose helical CT screening reduced lung cancer deaths by 20 percent, compared with standard chest X-rays. These dramatic results were first presented last November and were expanded in an online edition of the New England Journal of Medicine.

“The dramatic results of the NLST study provide us with a valuable initial indication for our LuCED test,” said Scarlett Spring, president of VisionGate. “By combining the high accuracy and cost effectiveness of our non-invasive LuCED diagnostic with the proven ability of CT screening to reduce lung cancer deaths, we hope to make mass screening feasible and affordable.”

For more information about VisionGate and its 3D imaging visit www.2011worldlungcancer.org or www.visiongate3D.com.

 

 Arizona Business Magazine September/October 2011